Fig. 3

NRF2 is significantly augmented in AML cells expressing the DNMT3A R882H mutation. A NRF2 mRNA expression in samples of AML with the DNMT3A-R882 mutation compared with that in samples of AML with DNMT3A -WT. B GSEA analysis was used to detect NRF2 pathway enrichment in AML patients with the DNMT3A R882 mutation C The Beat AML database was used to analyze survival rate based on NRF2 expression. D, E The expression of NRF2 and NQO1 mRNA expression in WT and mutant KG-1a and THP1 cells were detected by qPCR and western blotting. F, G The expression of NRF2 in the nucleus and cytoplasm of KG-1a and THP1 cells expressing NC, WT and R882H was evaluated by western blot. H Cytoplasmic localization of NRF2 in KG1 and THP1 cells expressing DNMT3A WT and R882H. Immunostaining with anti-NRF2 (red) and DAPI (blue). I, J Immunoblot of NRF2 and NQO1 expressions in DNMT3A WT and mutant KG-1a and THP1 cells after treated with different concentrations of DNR for 24 h. K, L Immunoblot of NRF2 and NQO1 expressions in DNMT3A WT and mutant KG-1a cells and THP1 cells after treated with 0.4 μM DNR and harvested at different times